Our diverse pipeline is designed to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.
|Product Candidate||Target||Indication||Discovery||Preclinical||IND/CTA||Phase 1||Phase 2||Phase 3||Filing||Approval/
Influenza A and B
|Seasonal Influenza|| |
|SCB-2019 (CpG 1018/Alum)(2)||SARS-CoV-2 S-Trimer
|≥ 1 Mid-to-Late Stage In-Licensed Vaccines(3)||-||Respiratory Vaccines (Pneumococcal, etc.) Pediatric Vaccines (EV71, Combination Pediatric, etc.)||
Phase 2 / Phase 3 / Approved Assets
|SCB-1019||RSV F-trimer||Respiratory Syncytial Virus (RSV)|
|Product Candidate||Target||Indication||Discovery||Preclinical||IND/CTA||Phase 1||Phase 2||Phase 3||Filing||Approved/
|SCB-219M(6)||TPO Mimetic Bispecific-Fc||Chemotherapy-Induced Thrombocytopenia (CIT)|
(Malignant Ascites, Malignant Pleural Effusions, Peritoneal Carcinomatosis)
We developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax's CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Phase 2/3 data from 30,000+ participants across five countries showed that SCB-2019 (CpG 1018/Alum) achieved 100% efficacy against severe COVID-19 and hospitalization caused by all strains of SARS-CoV-2 circulating during the trial, and a potentially best-in-field safety profile. To date, these trials have shown that SCB-2019 (CpG 1018/Alum) elicited a robust neutralization of variants including Omicron.
We have received emergency use authorization for SCB-2019 (CpG 1018/Alum) in China. In addition, we are pursuing regulatory submissions of SCB-2019 (CpG 1018/Alum) directly in select countries, primarily in Asia Pacific and Latin America.
AdimFlu-S (QIS) is a quadrivalent split inactivated vaccine intended for use in the prevention of influenza. As a quadrivalent vaccine, it contains hemagglutinin from four influenza virus strains (two A and two B), which increases its chances of achieving high vaccine effectiveness regardless of which influenza B strain becomes seasonally prevalent relative to trivalent options. AdimFlu-S (QIS) was approved by the China National Medical Products Administration in January 2022 for individuals aged three years and older.
Clover is developing XBB-Adapted SARS-CoV-2 Vaccine based on the Trimer-Tag technology platform, with development scheduled for completion in Year 2023.
Our respiratory syncytial virus (RSV) vaccine candidate (Fusion F Antigen-Trimer) induced a strong neutralizing antibody response in a rat immunization model. This candidate demonstrated high binding affinity (sub-picomolar) to palivizumab. Additional preclinical results and an update on development plans for this candidate are expected soon.
We continue to conduct preclinical studies to develop our rabies vaccine candidate. Additional preclinical results and an update on development plans for this candidate are expected soon.
We are conducting a Phase 1 trial for SCB-219M, an innovative human thrombopoietin receptor agonist (TPO-RA), for the treatment of chemotherapy-induced thrombocytopenia. Phase 1 data is expected in 2023.
We developed SCB-313 as a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. We believe SCB-313 has the potential to address the unmet global need for the treatment of intracavitary malignancies, including malignant ascites, malignant pleural effusions and peritoneal carcinomatosis.